Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2506 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-04-29

Study Completion Date

2024-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study D0817R00081 is a retrospective study using NCID database to assess the safety of Olaparib in Chinese patients with ovarian cancer by examining the incidence, seriousness, and severity of all AEs, including but not limiting to AESIs and SAEs, AEs related to Olaparib, and AEs leading to dose reduction, interruption or discontinuation of Olaparib. The first Olaparib prescription date will be set as the index date. The baseline period is from the patient's first ovarian cancer diagnosis recorded in the database to the patient's first treatment with Olaparib (as early as the database start date of January 1, 2013) to the index date for derivation of lines of therapy or one year pre-index date for other baseline variables. Patients will be followed until the patient's last medical record in the database, 30 days after the last dose of Olaparib, death, or June 30, 2023, whichever comes first. All patients who meet the inclusion/exclusion criteria will be enrolled.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Adverse Effects of Olaparib in Ovarian Cancer.

NCT04699006

Ovarian Cancer

ENROLLING_BY_INVITATION

Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting

NCT05153603

Ovarian Neoplasms

UNKNOWN

Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients

NCT04152941

Relapsed Ovarian Cancers Patients

COMPLETED

First-line Olaparib Combined With Bevacizumab Maintenance Therapy

NCT05440578

Ovarian Neoplasms

UNKNOWN

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

NCT02392676

Platinum Sensitive Relapsed Ovarian Cancer

WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Olaparib (Lynparza, formerly referred to as AZD2281 or KU-0059436), is a highly potent polyadenosine diphosphate ribose polymerase (PARP) inhibitor and the first in class approved for use in monotherapy (including maintenance therapy) as well as in combination with other chemotherapeutic agents. It is available in two strengths, 150mg and 100mg. The recommended dosage for Olaparib is 300mg (two 150mg tablets) taken twice daily, resulting in a total daily dose of 600mg. The 100mg strength tablet is used for dose reduction purposes. In August 2018, based on the findings of the trials, Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer (Study 19, NCT00753545) and Olaparib Treatment in Breast Cancer Gene (BRCA) Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy (SOLO-2, NCT01874353), China National Medical Products Administration (NMPA) approved Olaparib tablets for the maintenance treatment of adult patients with platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer,or primary peritoneal cancer who have achieved a complete or partial response to platinum-bSAEd chemotherapy. In November 2019, based on the results of the trial, Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy (SOLO-1, NCT01844986), Olaparib received approval for the maintenance treatment of treatment-naïve adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have germline BRCA mutations (gBRCAm) or somatic BRCA mutations (sBRCAm) and have achieved a complete or partial response to first-line platinum-based chemotherapy in China. Furthermore, in September 2022, based on the in PAOLA-1 study in front-line advanced ovarian cancer (NCT02477644), Olaparib in combination with Bevacizumab was approved for the maintenance treatment of adult patients with homologous recombination deficiency (HRD)-positive advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have achieved a complete or partial response to first-line platinum-based chemotherapy in China. Lynparza has been reported to be associated with mild or moderate adverse reactions \[grade 1 or 2 according to the Common Terminology Criteria for Adverse Events (CTCAE)\] and generally not requiring treatment discontinuation. In accordance with the Measures for the Administration of Adverse Drug Reaction Reporting and Monitoring (Order No.81 of the Ministry of Health), it is recommended to monitor the safety profile of newly approved drugs in real-world settings. Post-marketing real-world studies closely reflect clinical practice and provide a comprehensive understanding of the product's safety profile compared to premarketing Phase II/III studies. Currently, there is a limited number of safety studies focusing on Chinese patients with ovarian cancer conducted in routine clinical practice, and these studies have small sample size. This study aims to assess the safety of Olaparib in Chinese ovarian cancer patients treated in real-world clinical practice by retrospectively analysing electronic medical records (EMR) of ovarian cancer patients who received Olaparib in China from August 2018 to June 2023, documented in the National Cancer Information Database (NCID).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Using NCID Database to Assess the Safety of Olaparib in Chinese Patients With Ovarian Cancer by Examining the Incidence, Seriousness, and Severity of All AE

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients newly diagnosed with advanced or platinum sensitive recurrence epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (FIGO stage III-IV) treated with Olaparib+/-Bevacizumab according to approved label indications in China;
2. Patients with at least one prescription record of Olaparib between August 01, 2018 and June 30, 2023;
3. Age ≥18 years at first use of Olaparib;
4. At least one visit record after the first use of Olaparib.

Exclusion Criteria

* Patients enrolled in the other Olaparib DIM Programs (D0816C00016 and D0817R00011) conducted by AstraZeneca.
* Patients newly diagnosed with stage I and stage II ovarian cancer

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No